KV Pharmaceutical's Launch of Gestiva(TM) Delayed

Tuesday, January 27, 2009 General News J E 4
ST. LOUIS, Jan. 26 KV Pharmaceutical(NYSE: KVa/KVb) has been notified that the pending New Drug Application (NDA)for Gestiva(TM) (alpha hydroxyprogesterone caproate) will not be approved bythe U.S. Food and Drug Administration (FDA) until further conditions are met.

As previously disclosed, KV Pharmaceutical entered into a purchaseagreement to acquire the U.S. and worldwide rights to Gestiva upon approval ofthe pending NDA, which was under review by the FDA. The Company previouslyannounced that the date on which the FDA was expected to issue a decision wasJanuary 25, 2009.

The Company has been informed by the current NDA applicant that the FDAwill not approve Gestiva until additional data and information is submittedand accepted. The NDA applicant and the Company have agreed to certain FDA-suggested revisions to the protocol for a post-approval clinical trial thatthe parties had previously agreed to conduct. However, the agency has nowconcluded that an additional condition for approval, among others, will bethat a portion of the study subjects must be enrolled in the study prior tofinal approval. As a result, the Company does not anticipate that it willgenerate revenues from sales of Gestiva during this fiscal year, which ends onMarch 31, 2009.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceuticalcompany that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceuticalproducts. The company markets its technology distinguished products throughETHEX Corporation, a national leader in generic pharmaceuticals and Ther-RxCorporation, its branded drug subsidiary.

SOURCE KV Pharmaceutical


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
University of Michigan's Zell Lurie Institute Welc...
KV Pharmaceutical Suspends Product Manufacturing, ...